Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22075155 | 0.88 | ACVR1 (0.35) | ACVR1TGFBR1MAPK14ROCK2MET | |
| SCHEMBL22075305 | 0.84 | PIM1 (0.36) | TGFBR1ROCK2METPDGFRBPDGFRA | |
| SCHEMBL22075061 | 0.83 | TNIK (0.41) | TNIKIDO1TGFBR1MAPK14 | |
| SCHEMBL22075360 | 0.82 | FEN1 (0.37) | TGFBR1ROCK2METPDGFRBPDGFRA | |
| SCHEMBL25084517 | 0.81 | TGFBR1 (0.44) | TNIKACVR1TGFBR1MAPK14ROCK2 | |
| SCHEMBL22075158 | 0.80 | TNIK (0.42) | TNIKIDO1TGFBR1MAPK14PDGFRB | |
| SCHEMBL22074805 | 0.76 | HTR6 (0.44) | TNIKMET | |
| SCHEMBL22074906 | 0.76 | MAPK14 (0.39) | TNIKIDO1MAPK14MET | |
| SCHEMBL22075246 | 0.75 | MAPK14 (0.35) | TNIKIDO1TGFBR1MAPK14 | |
| SCHEMBL22074971 | 0.75 | KDM4E (0.37) | MAPK14AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2020123453-A2 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952996-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | TNIK 176/4885ACVR1 2/4885IDO1 3400/4885 |
| US-20210154178-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | TNIK 176/4885ACVR1 2/4885IDO1 3400/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | TNIK 176/4885ACVR1 2/4885IDO1 3400/4885 |
| US-20200188370-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | TNIK 176/4885ACVR1 2/4885IDO1 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.